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Abstract
Currently, few rodent models of AIDS-associated non-Hodgkin’s lymphoma (AIDS-NHL) exist. In these studies, a
novel mouse/human xenograft model of AIDS-associated Burkitt lymphoma (AIDS-BL) was created by injecting cells
of the human AIDS-BL cell line, 2F7, intraperitoneally into NOD-SCID mice. Mice developed tumors in the peritoneal
cavity, with metastases to the spleen, thymus, and mesenteric lymph nodes. Expression of the chemokine receptor,
CXCR5, was greatly elevated in vivo on BL tumor cells in this model, as shown by flow cytometry. CXCL13 is the
ligand for CXCR5, and serum and ascites levels of murine, but not human, CXCL13 showed a striking elevation in
tumor-bearing mice, with levels as high as 200,000 pg/ml in ascites, as measured by ELISA. As shown by
immunohistochemistry, murine CXCL13 was associated with macrophage-like tumor-infiltrating cells that appeared to
be histiocytes. Blocking CXCR5 on 2F7 cells with neutralizing antibodies prior to injection into the mice substantially
delayed tumor formation. The marked elevations in tumor cell CXCR5 expression and in murine CXCL13 levels seen
in the model may potentially identify an important link between tumor-interacting histiocytes and tumor cells in AIDS-
BL. These results also identify CXCL13 as a potential biomarker for this disease, which is consistent with previous
studies showing that serum levels of CXCL13 were elevated in human subjects who developed AIDS-lymphoma.
This mouse model may be useful for future studies on the interactions of the innate immune system and AIDS-BL
tumor cells, as well as for the assessment of potential tumor biomarkers for this disease.
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Introduction
The most common subtypes of AIDS-associated non-
Hodgkin’s lymphoma (AIDS-NHL) are Burkitt lymphoma (BL),
diffuse large B cell lymphoma (DLBCL), and primary central
nervous system lymphoma (PCNSL) [1,2]. It is thought that
many of these tumors result from hyperactivation of B cells,
which occurs in HIV infection and can contribute to genetic
damage that leads to tumorigenesis [3]. Work by McGrath et al.
suggests that tumor-infiltrating cells play an important role in
AIDS-lymphoma pathogenesis [4–6]. Specifically, about half of
AIDS-NHLs were seen to contain tumor-associated
macrophages (TAM), many of which appeared to be infected
with HIV strains that were resistant to combination anti-
retroviral therapy (cART) [4,7]. Furthermore, macrophages
from human AIDS-lymphomas of the more rare primary
effusion lymphoma (PEL) subtype were shown to be able to
induce lymphoma formation when injected into
immunodeficient SCID mice [6]. In this case, the induced
tumors appeared to be T cell lymphomas of murine origin;
however, the lymphomagenic potential of these macrophages
was clear.
CXCL13 (BLC, BCA-1) is a chemokine most known for
regulating the homeostatic movement of mature B cells through
secondary lymphoid tissue [8]. It can also be induced during
certain types of inflammatory processes, such as rheumatoid
arthritis and Sjögren’s syndrome, where it aids in the formation
of ectopic lymphoid tissues, and thus promotes the disease
process [9,10]. Recently, we demonstrated that serum levels of
CXCL13 are substantially increased during HIV infection [11].
The receptor for CXCL13 is CXCR5 (BLR1) [8], and it has been
shown that levels of CXCR5 are significantly decreased on the
surface of circulating B cells during HIV infection, and that
these cells, in contrast to B cells from healthy individuals,
express CXCL13 [12,13]. These results suggest that CXCL13
could potentially play a role in the B cell hyperactivation
observed during HIV infection that is believed to contribute to
AIDS-NHL formation.
CXCL13 has been more directly implicated in the biology of
some B cell tumors, including several non-HIV-associated
lymphomas, such as follicular lymphoma and primary
intraocular lymphoma [14,15]. In the case of primary intraocular
lymphoma, tumor cells expressed CXCR5, and adjacent non-
cancerous ocular cells expressed CXCL13, suggesting that
these ocular cells might be directing tumor growth [14]. In other
lymphomas, CXCL13 induced chemotaxis of tumor cells
[16,17]. Recently, we showed that serum levels of CXCL13
were elevated in preceding AIDS-NHL diagnosis [18].
Furthermore, CXCR5 and/or CXCL13 were expressed in most
primary AIDS-NHL tumor specimens. Several AIDS-NHL cell
lines, including the AIDS-BL cell line, 2F7, also demonstrated
chemotaxis towards CXCL13 in vitro [18].
As few mouse models of AIDS-lymphoma currently exist, our
aim in these studies was to create a mouse/human xenograft
model of AIDS-BL and to evaluate CXCR5 and CXCL13
expression in this model. Tumors readily formed intra-
abdominally in NOD-SCID mice after intraperitoneal (i.p.)
injection of cells of the AIDS-BL cell line, 2F7. Furthermore,
cells of AIDS-BL tumors growing in the mice showed greatly
elevated surface expression of CXCR5. High levels of murine,
but not human, CXCL13, also were seen in these animals, and
tumors contained tumor-infiltrating cells that stained positively
for murine CXCL13 by immunohistochemistry.
Materials and Methods
Ethics statement
The AIDS-lymphoma cell lines, 2F7, R, and BCBL-1 are of
human origin, but are long-established cell lines that have
previously been described in the literature and that were
obtained commercially or from other sources without any
information that would identify the subjects from whom they
were derived [20]. This study, therefore, did not involve the use
of human subjects, and was not subject to Institutional Review
Board (IRB) review. All animal experiments were carried out in
strict accordance with the Policy on Humane Care and Use of
Laboratory Animals of the United States Public Health Service.
The protocol was approved by the Animal Research Committee
(ARC) at UCLA (Assurance # A3196-01). Isoflurane was used
for euthanasia and to anesthetize animals during i.p. injections
of tumor cells and when restraint of animals was needed for
PET imaging. All efforts were made to minimize suffering.
Cell lines
The AIDS-BL cell line, 2F7, was obtained from the American
Type Culture Collection (ATCC; Rockville, MD), and has been
previously described [19]. It was derived from an AIDS-BL, and
is positive for the Epstein–Barr virus (EBV), negative for HIV,
and expresses the B cell markers, CD19 and CD20, but not the
CD3 T cell marker, on its cell surface [19,20]. This cell line was
cultured in standard media as previously described [20]. The
AIDS-lymphoma cell lines, R (AIDS-DLBCL subtype), and
BCBL-1 (primary effusion lymphoma [AIDS-PEL] subtype),
were obtained and cultured in standard media as described
[20]. The R cell line is EBV(+), whereas the BCBL-1 cell line is
EBV(-), but positive for human herpesvirus-8 (HHV-8) [20].
Flow cytometry
Cell surface expression of the chemokine receptor, CXCR5,
was examined by flow cytometry using an indirect staining
protocol as previously described [18,20]. Briefly, cells were
incubated with a rat IgG2b anti-CXCR5 antibody; as a control,
other cells were incubated with a rat IgG2b isotype control
antibody. Samples were then incubated with a phycoerythrin
(PE)-conjugated goat anti-rat IgG secondary antibody, and cell
fluorescence was measured by flow cytometry. During data
collection, at least 5,000 cells/events were acquired per tube/
condition. Dead cells were excluded from the analysis using
forward- and side-scatter. For all flow cytometry studies, data
were acquired using a Becton Dickinson LSR machine, and
analyzed using CellQuest Pro 5.1 software (Becton Dickinson,
Franklin Lakes, New Jersey, USA).
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Animals
Immunodeficient female NOD-SCID (NOD/LzSz-
Prkdc(SCID)/J) mice, 8-12 weeks of age, were purchased from
The Jackson Laboratory (Bar Harbor, Maine, USA).
In vivo studies
To create a mouse/human xenograft model of AIDS-BL, 106
2F7 cells in saline were injected i.p. into mice. Control animals
were injected with saline alone. Mice were also injected i.p.
with 106 cells of the R cell line (AIDS-DLBCL), or of the BCBL-1
cell line (AIDS-PEL). Typically, mice developed palpable
tumors in the abdomen at 5-10 weeks after inoculation with the
cell lines. These tumors were reducible to single-cell
suspensions when placed in culture media. After filtering
through 100-µm pore size cell strainers (Becton Dickinson),
and washing in media to remove debris, cells could readily be
used in in vitro studies. For CXCR5 neutralization experiments
in the 2F7 AIDS-BL model, a monoclonal anti-human CXCR5
antibody (Clone 51505, mouse IgG2B) with known neutralizing
activity to CXCR5 was obtained in a low-endotoxin format from
R&D Systems (Minneapolis, Minnesota, USA). An isotype
control antibody was also obtained from R&D Systems (Clone
20116, mouse IgG2B). For these experiments, cultured 2F7
cells (106 cells/ml) were incubated at 37° C in the presence of
10 µg/ml of neutralizing or control antibody for 40 minutes.
Cells were then centrifuged and resuspended in sterile
pharmaceutical-grade saline, and 106 cells were injected i.p.
into NOD-SCID mice as per the standard model. Mice were
then monitored for tumor development.
Imaging of animals
Imaging studies of animals injected with 2F7 cells were
performed in the Crump Institute for Molecular Imaging at
UCLA. For positron emission tomography (PET) imaging, mice
were first injected via the tail vein with 200-300 µCi of [18F]-
Fluorodeoxyglucose (FDG). After 60 minutes, mice were then
scanned over a 10-minute period using a Focus 220 microPET
scanner (Siemens Preclinical Solutions, Knoxville, Tennesse,
USA). Finally, MicroCT scanning was performed for 10 minutes
using a microCAT II (Concorde Microsystems, Knoxville,
Tennessee, USA) instrument. The AMIDE software program
(Version 0.9.2) was used to co-register PET and CT scans to
create a single image for each mouse, as previously described
[21,22].
Determination of CXCL13 levels
Levels of murine and human CXCL13 in serum and in tumor
ascites fluid were determined by ELISA, using kits validated to
be specific for either murine or human CXCL13 (Quantikine™,
R&D Systems), with no cross-reactivity. The manufacturer’s
protocols were followed in performing the assays. The lower
limit of detection of the murine CXCL13 assay was 15.6 pg/ml;
for human CXCL13 the limit was 7.8 pg/ml.
Estimation of murine CXCL13 levels in the peritoneal
fluid of healthy NOD-SCID mice
The abdominal cavities of healthy control female NOD-SCID
mice (n = 7) were lavaged using serum-free RPMI-1640
medium. Lavage fluid was then concentrated using a protocol
similar to one that has been previously described [23]. Briefly,
lavage fluid from animals was pooled to give a total volume of
20 ml, and then concentrated 25-fold using an Amicon Ultra-15
centrifugal unit (Millipore, Billerica, Massachusetts, USA)
designed to retain molecules with a mass greater than 3 KDa.
The concentrate was then stored at -80° C until further use.
To estimate background murine CXCL13 levels in the
peritoneal fluid of these mice, levels of murine CXCL13 were
then measured in this concentrate by ELISA, and determined
to be 3942 pg/ml. The estimated level of murine CXCL13 in the
peritoneal cavity prior to lavage was calculated using the
formula: ((3942 pg/ml)/25) x (20 ml total pooled lavage fluid/7
mice)) / (estimated volume of peritoneal fluid in each mouse
prior to lavage). As the actual volume of peritoneal fluid in
these mice was very small, it was not possible to measure it
directly prior to lavage. Assuming a peritoneal fluid volume of
0.05 ml per mouse led to an estimated murine CXCL13 level of
~9,000 pg/ml in peritoneal fluid, while assuming an average
volume of 0.5 ml led to an estimated CXCL13 concentration of
~900 pg/ml.
Immunohistochemistry
Immunohistochemistry studies on tumors from mice injected
with 2F7 cells were performed on formalin-fixed, paraffin-
embedded tumor sections by the Translational Pathology Core
Laboratory in the Department of Pathology & Laboratory
Medicine at UCLA. For staining for human CXCR5, murine
CXCL13, and human CXCL13, sections (4 µm thickness) were
first processed as previously described [18], except that the
wash buffer used was phospho-buffered saline with Tween
(PBST). These processing steps included antigen retrieval
treatments and treatments to quench endogenous peroxidase.
For CXCR5, sections were stained using identical reagents as
previously described [18], except that the primary antibody
staining step was followed by a 30 minute incubation with a
secondary biotinylated polyclonal rabbit anti-rat
immunoglobulin antibody reagent (Cat. #E0468, Dako,
Carpinteria, California, USA) at a 1:200 dilution. The signal was
detected using the rabbit horseradish peroxidase EnVision kit
(DAKO), which included the use of anti-rabbit HRP polymer
and diaminobenzidine (Cat. # 32741, Sigma-Aldrich, St. Louis,
Missouri, USA) as the reaction substrate. The sections were
counterstained with hematoxylin. As a control, serial sections
were incubated with an isotype control antibody as previously
noted [18]. Serial sections were also stained with hematoxylin
and eosin (H&E).
For human CXCL13, sections were incubated with primary
antibody as previously described [18]. A similar protocol was
used for murine CXCL13, except that the primary antibody was
a specific polyclonal goat IgG (R&D Systems), used at a
concentration of 15 µg/ml. Normal goat IgG (Santa Cruz
Biotechnology, Santa Cruz, California, USA) was used as a
control. Subsequent steps in the staining protocol for both
Elevated CXCL13 in a Mouse Model of AIDS-Lymphoma
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human and murine CXCL13 were identical to those for CXCR5
(above).
For F4/80 (murine histiocyte marker) staining, endogenous
peroxidase activity was first blocked with 3% hydrogen
peroxide in methanol for 10 minutes. Next, proteolytic induced
epitope retrieval (PIER) was carried out with proteinase K (Cat.
#S3020, Dako) for 10 minutes at 37° C. Sections were then
stained overnight at 4° C with monoclonal rat anti-mouse F4/80
(Cat. # MCA497b, clone CI:A3-1, IgG2b, AbD Serotec, Raleigh,
North Carolina, USA) at a dilution of 1:50. Subsequent steps
were identical to those in the CXCR5 staining protocol (above).
All stained slides were scored and photographed by a
pathologist (JWS). Pictures were taken using an Olympus
DP-25 camera attached to an Olympus BX51 bright field
microscope, and recorded on a Smart Media digital card. The
20X objective lens (UPlan Apo, Japan) used to take the
pictures had an aperture of 0.70. Pictures were edited for
publication using Canvas 5.0.3 (ACD Systems of America, Inc.,
Miami, Florida, USA).
Statistical analysis
The statistical significance of differences in CXCL13 levels
between two experimental groups was evaluated using a 2-
tailed Student’s t-test. If variances between groups were
unequal, then the unequal-variances form of the test was used.
Data were log-transformed to meet model assumptions,
although they are given in linear scale for ease of presentation.
Pearson product moment correlation was used to assess the
correlation between mCXCL13 levels in the serum and in the
ascites of mice with tumors. For survival studies of mice with
tumors, survival rates in different experimental groups were
compared using the method of Kaplan-Meier and the log-rank
test. All analyses were conducted using SAS Version 9.2 (SAS
Institute, Inc., Cary, North Carolina, USA).
Results
Tumors consistently form in NOD-SCID mice inoculated
with the human AIDS-NHL cell lines, 2F7, R and BCBL-1
Mice consistently developed tumors within the peritoneal
cavity about 8-10 weeks after i.p. injection of 106 2F7 cells
(Figure 1). Metastases to the spleen, thymus, and mesenteric
lymph nodes were common in this model (not shown). Tumors
bore a significant resemblance to human BL on histopathology
examination in that they were made up of intermediate-sized
cells that contained round oval nuclei, distinct nucleoli, and had
a blast-like appearance (Figure 2A). Scattered “starry sky”
macrophages were present (Figure 2A). When examined using
flow cytometry, tumor cells from both primary tumors and
metastases uniformly expressed the human pan-B cell
markers, CD19 and CD20, on their cell surface, similar to cells
of the 2F7 cell line grown in vitro [19,20] (not shown). Tumor
cells were also occasionally present in the brains of some
animals, as cells positive for human CD19 and human CD20
were sometimes present in cell suspensions from the brains of
animals with intra-abdominal primary 2F7-derived tumors, as
demonstrated by flow cytometry (data not shown). Such cells
were never present in the brains of control animals (not
shown). PET images of mice with tumors also were
occasionally suggestive of brain metastases (see Figure 1, for
example). However, more detailed studies of possible brain
metastases were not performed.
Mice injected i.p with R cells (AIDS-DLCBL subtype) also
developed intra-abdominal tumors, whereas several mice
injected with BCBL-1 cells (AIDS-PEL subtype) formed intra-
abdominal effusions (data not shown). However, extensive
studies of R- and BCBL-1-derived tumors were not performed.
2F7-derived tumors express greatly elevated levels of
the chemokine receptor, CXCR5
The 2F7 cell line, when grown in culture, showed modest
surface expression of human CXCR5 (Figure 3). In contrast,
cells isolated from in vivo tumors derived from 2F7 cells
showed greatly elevated levels of CXCR5 expression (Figure
3). This striking elevation in CXCR5 expression was seen
uniformly on all tumors in these mice, both primary (Figure 3)
and metastatic (not shown). Immunohistochemistry studies
(Figure 2B-C) also confirmed the expression of human CXCR5
by tumor cells.
Levels of murine, but not human, CXCL13 are greatly
elevated in both the serum and ascites of mice with
2F7-derived AIDS-BL tumors
To assess human CXCL13 levels in the 2F7 AIDS-BL model,
serum and tumor ascites were collected from seven mice that
had end-stage tumors, and CXCL13 levels were then
measured using ELISA specific for human or murine CXCL13.
In all cases, no human CXCL13 was detected (not shown).
Similar results were seen in serum or ascites fluid from the
animals that developed tumors after being inoculated with the
R or BCBL-1 cell lines (data not shown).
In contrast, serum murine CXCL13 levels were found to have
increased ~20-fold in animals that developed tumors (p <
0.00002) (Figure 4A). Murine CXCL13 levels in tumor ascites
were generally extremely high, with an average value of nearly
200,000 pg/ml (Figure 4B). These results were replicated in
additional independent experiments (not shown). There was a
correlation between serum and ascites murine CXCL13 levels
in individual mice (Pearson’s correlation coefficient = 0.532, p =
0.049).
Detailed studies of tumors in mice injected with R (AIDS-
DLBCL) cells or BCBL-1 (AIDS-PEL) cells were not performed.
However, the animals that developed R- or BCBL-1-derived
tumors (n = 2 /group) all showed greatly elevated serum levels
of murine CXCL13 (ranging from about 10,000 to 40,000 pg/
ml), and in tumor ascites fluid (ranging from about 25,000 to
100,000 pg/ml).
As noted in the Materials and Methods, an attempt was
made to estimate background murine CXCL13 levels in the
peritoneal cavity of normal control NOD-SCID mice, which
resulted in a low estimate of ~900 pg/ml, and a high estimate of
~9,000 pg/ml. Both of these estimates are much lower than the
median murine CXCL13 level seen in the ascites of mice
bearing 2F7-derived tumors (shown in Figure 4B).
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Murine CXCL13 is associated with tumor-infiltrating
cells of mouse origin in tumors in the 2F7 AIDS-BL
model
Expression of human CXCR5, human CXCL13, murine
CXCL13, and the mouse histiocyte marker, F4/80, were
examined by immunohistochemistry in both primary tumors and
metastases from mice inoculated with 2F7 cells as noted in the
Materials and Methods. Representative results are shown in
Figure 2. Tumors typically expressed human CXCR5 (Figure
2B-C), consistent with the flow cytometry results shown in
Figure 3. In contrast, a negligible expression of human
CXCL13 was generally seen (Figure 2C-D), which is consistent
with the results of serum/ascites studies described earlier.
Interestingly, both primary tumors (shown) and metastases (not
shown) all contained what appeared to be infiltrating,
macrophage-like non-tumor cells that strongly stained positive
for murine CXCL13 (Figure 2E). To determine what type of
cells these were, serial tumor sections were stained using
antibodies to the mouse histiocyte marker, F4/80, and for
murine CXCL13. As shown in Figure 2F, tumors were
consistently infiltrated with F4/80+ cells. Cells that were F4/80+
and cells that were murine CXCL13+ were present in
sequential serial sections (Figure 2G-H). Furthermore, both
F4/80+ and murine CXCL13+ cells had a phenotype similar to
that of a histiocyte, which included the presence of dendritic
processes on some cells (Figure 2G-H). These results are
consistent with the murine CXCL13+ tumor-infiltrating cells
being mouse histiocytes.
Figure 1.  Images of 2F7-derived AIDS-Burkitt lymphoma (BL) tumors in NOD-SCID mice.  (A) A picture showing three tumors
growing in the peritoneal cavity, as indicated by arrows. The left tumor is located on an ovary; the middle tumor is in the mesentery,
and the tumor to the right is under the abdominal wall. Brown areas are intestines. (B) PET images of a healthy control mouse that
was not inoculated with tumor cells (left two panels), and of a mouse with advanced peritoneal tumors (right two panels). Animals
were imaged 1 hour after i.v. injection of [18F]-FDG. Coronal and sagittal images are shown. The color scale indicates the relative
intensity of radioactivity levels, with black representing the lowest level and red the highest. H = heart; T = tumor masses; B =
bladder.
doi: 10.1371/journal.pone.0072414.g001
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Blocking the interaction of CXCL13 with its receptor,
CXCR5, results in a substantial delay in 2F7 AIDS-BL
tumor formation in mice
To determine if human CXCR5 plays an essential role in the
formation of 2F7-derived BL tumors in this model, mice (n = 6)
were injected i.p. with 2F7 cells that had been pre-incubated
with a neutralizing antibody to human CXCR5, as noted in the
Materials and Methods. Control animals (n = 6) were injected
with 2F7 cells that had been pre-incubated with an isotype
control antibody. As shown in Figure 5, tumor formation in the
anti-CXCR5 treatment group was substantially delayed, with
the median time to death in this group being 120.5 days (95%
CI = 90-161 days), compared to 73 days (95% CI = 62-77
days) for the control group (p < 0.0007, log-rank test); this
represents a 65% increase in the time to death in the treatment
group. Two additional replicates of this experiment were
performed, with similar results.
Discussion
In these studies, a novel mouse/human xenograft model of
AIDS-BL was created by injecting NOD-SCID mice i.p. with the
AIDS-BL cell line, 2F7. In this model, mice reliably develop
tumors in the peritoneal cavity, with metastases to other
locations (Figure 1). The development of this model is
significant, because to date few tractable animal models of
AIDS-related BL exist. Monkeys infected with simian
immunodeficiency virus (SIV) will sometimes develop Burkitt-
like (BL) lymphomas [24]. However, monkeys are expensive
and difficult to work with, and only a small proportion of SIV-
infected animals will develop BL-like tumors [24]. Laurence et
al. [25] reported that a subset of human B cells could be
infected with HIV in vitro and would then develop a malignant
phenotype, becoming capable of producing Burkitt-like tumors
when injected subcutaneously into SCID mice. However,
human AIDS-BL tumor cells are typically not infected with HIV
[26]. Several mouse/human xenograft models of BL unrelated
to HIV infection have been described [27,28]; however, to our
Figure 2.  Expression of CXCR5 and CXCL13 on 2F7-derived AIDS-BL tumor cells in NOD-SCID mice, by
immunohistochemistry.  Immunohistochemistry was performed as described in the Materials and Methods, using an HRP/DAB
color development system with hematoxylin counterstaining. Some sections were stained with both hematoxylin and eosin (H and
E). Typical staining results for each marker are given in the figure as follows: (A) H and E, (B) human CXCR5, (C) a representative
negative control, (D) human CXCL13, (E) murine CXCL13, and (F) F4/80. The results of the H&E staining in (A) show a tumor that
in many respects resembles human BL, which typically contain significant numbers of infiltrating macrophages, giving a “starry sky”
appearance (see arrows). The corner insert in (A) shows a 3-fold enlargement of the area in the image to which the upper arrow
points, with such a macrophage in the center of the enlargement. The image in (E) shows that tumors appear to be infiltrated with
scattered cells that stain positive for murine CXCL13. In an attempt to more precisely determine the cell type of these infiltrating
cells serial tumor sections were stained separately for murine CXCL13 and for F4/80, and images of the resulting staining were
enlarged 3-fold compared to the images in (A–F) to provide more detail (G, H). In (G) and (H), both mCXCL13(+) and F4/80(+) cells
appear to be large cells that sometimes have dendritic processes. All images shown in this figure were taken at an original
magnification of 200X. Each image contains an internal scale marker that is 100 microns in length.
doi: 10.1371/journal.pone.0072414.g002
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knowledge, the expression of CXCL13 been not been reported
in these models. In one model of particular interest, NOD-SCID
mice formed tumors in the peritoneal cavity that significantly
resembled BL after i.p. injection of the Namalwa EBV(+) non-
AIDS-associated BL cell line [27]. Interestingly, the chemokine,
CXCL12 (SDF-1), and its receptor, CXCR4, played an
essential role in development of tumors in this model, as
blockade of these molecules abrogated tumor growth [29].
Figure 3.  CXCR5 expression is greatly elevated on cells of 2F7-derived AIDS-BL tumors in NOD-SCID mice.  The left panel
shows CXCR5 expression, as determined by flow cytometry, on cells of the AIDS-BL cell line, 2F7, growing in culture; the right
panel shows expression on 2F7-derived tumors growing in NOD-SCID mice. Data are presented as histograms, with relative
fluorescence intensity given on the x-axis and cell counts given on the y-axis. For both panels, cells were stained for CXCR5
expression using an indirect staining protocol, as noted in the Materials and Methods; the secondary antibody was labeled with
phycoerythrin (PE). Open histograms show staining for CXCR5; closed histograms show staining with isotype control antibody.
doi: 10.1371/journal.pone.0072414.g003
Figure 4.  Murine CXCL13 levels are greatly elevated in the serum and ascites of mice with 2F7-derived AIDS-BL
tumors.  (A) Murine CXCL13 levels in the serum of control mice (n = 13) and in the serum of mice with tumors (n = 14), as
determined by ELISA. (B) Murine CXCL13 levels in the ascites fluid of the mice with tumors. The solid square within each box plot
represents the mean value for the data. In (A), there is an ~20-fold increase in mean mCXCL13 levels in the serum of mice with
tumors compared to control mice (p < 0.0001; t-test). In (B), the long lower whisker in the box plot of the data reflects the presence
of several low outliers; these lower values were generally seen in animals that developed smaller, more localized tumors at the site
of injection as opposed to widespread metastatic disease.
doi: 10.1371/journal.pone.0072414.g004
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However, expression of CXCR5 or CXCL13 was not examined
in that model.
Because both the 2F7 cell line and Namalwa cell lines are
similar in that they are EBV(+) BL cell lines, we initially studied
CXCR4/CXCL12 in our model, but found no indications that
these molecules were important in promoting tumor growth in
this model (unpublished results). Instead, surface expression of
CXCR5 was seen to be greatly elevated on cells of 2F7-
derived tumors in the model (Figure 3). While human CXCL13
was undetectable in serum or ascites fluid from animals with
tumors (Results, not shown), levels of murine CXCL13 were
greatly elevated in these fluids (Figure 4). These findings are
significant for the following reasons: first, this is, to the best of
our knowledge, the first report of CXCL13 overexpression in
any mouse model of BL, HIV-associated or not. Second, these
results are consistent with our previously published results that
most primary human AIDS-lymphomas, including tumors of the
Burkitt subtype, were positive for both CXCR5 and CXCL13
expression, and that serum levels of CXCL13 were elevated in
subjects who developed AIDS-lymphoma [18]. The results of
the current study thus provide additional evidence that these
molecules are overexpressed in AIDS-lymphoma, and that
CXCL13 is a potential biomarker for this disease. The
overexpression of these molecules in this mouse model also
helps validate the model as successfully recapitulating aspects
of human AIDS-BL. Third, the fact that high levels of murine,
but not human, CXCL13 are present in the serum and ascites
Figure 5.  Inhibition of CXCR5 substantially increases
length of survival in the 2F7 NOD-SCID mouse model of
AIDS-BL.  In one group of mice (n = 6), 2F7 cells were pre-
incubated with neutralizing antibody to CXCR5 prior to injection
into mice. In the control group (n = 6), cells were pre-incubated
with an isotype control antibody. The figure depicts a survival
curve for the experiment. The number of days elapsing since
the injection of 2F7 cells is shown on the x-axis, and the
percentage of surviving mice is shown on the y-axis. The solid
line depicts results for the anti-CXCR5 test group; the dotted
line depicts results for the isotype control group. These results
are significant (p < 0.0007, log-rank test). Two additional
replicates of this experiment have been performed, with similar
results.
doi: 10.1371/journal.pone.0072414.g005
fluid of animals with 2F7-derived tumors suggests that non-
tumor mouse cells are responsible for CXCL13 production in
this model. The immunohistochemistry results (Figure 2) further
confirm this, as they indicate that the tumors are infiltrated with
mouse cells (probably histiocytes) that show positive staining
with antibodies against murine, but not human, CXCL13.
Further studies are needed to definitively identify the actual
mouse cells producing murine CXCL13 in this model, since the
CXCL13(+) tumor-infiltrating cells might merely be binding
circulating chemokine, which is present at very high levels.
These results raise the possibility that tumor-infiltrating cells
could potentially be a significant source of the elevated levels
of CXCL13 that are seen in the human disease. Fourth, the fact
that differential levels of human and murine CXCL13 are
readily seen in the model and are readily identifiable as being
produced by tumor (human CXCL13) or non-tumor (murine
CXCL13) cells, suggests that this model could have substantial
potential utility for determining the source of other molecules
that are known to be over-produced in persons who develop
AIDS-lymphoma, such as soluble CD23 and IL-6 [30,31].
Similarly, the mouse model should be useful for studies to
determine how tumor cells and cells of the immune system
interact with each other.
The finding that tumors in the 2F7 model are infiltrated by
mouse cells, some of which bear the mouse histiocyte marker,
F4/80 (Figure 2F and 2H), and some of which stain positively
for murine CXCL13 (Figure 2E and 2G), has additional
significance. It has been reported that a substantial proportion
of AIDS-lymphomas are infiltrated by histiocyte-type cells, such
as macrophages [4,5]. The fact that this is seen in the NOD-
SCID mouse model provides additional evidence that the
model is able to recapitulate processes occurring in AIDS-
lymphoma in humans. This histiocyte infiltration is particularly
interesting in view of the work of McGrath et al. [6], who noted
that isolated tumor-infiltrating macrophages from AIDS-
lymphomas are able to promote tumor formation in SCID mice.
The results in the 2F7 NOD-SCID model suggest that the
reverse may also be true: AIDS-lymphoma tumor cells may
also be able to attract and activate tumor-infiltrating cells, such
as histiocytes, which may then possibly potentiate the growth
of the tumor cells.
Our results identify CXCL13 as potentially being an important
molecule linking the innate immune system and tumor cells in
the pathogenesis of AIDS-lymphoma. We have previously
reported that 2F7 cells show chemotaxis towards human
CXCL13 in vitro [18]; others have reported or inferred that
murine CXCL13 can act on human CXCR5, and that human
CXCL13 can induce proliferation of tumor cells in some
cancers [32,33]. The high levels of CXCR5 and murine
CXCL13 that are seen in the 2F7 model thus raises the
possibility, although does not prove, that murine CXCL13
(possibly produced by tumor-infiltrating cells) acts to promote
tumor growth. The fact that pre-incubation of 2F7 cells with
neutralizing antibody to CXCR5 substantially delays the time to
death in the model (Figure 5) provides additional evidence that
the CXCR5/CXCL13 axis could potentially be playing an
important role in tumor development in the model. Results from
these latter studies should be interpreted with caution, though,
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since it remains possible that antibody-bound 2F7 cells are
being killed in the mice by mechanisms such as antibody-
dependent cell-mediated cytotoxicity (ADCC). This possibility
seems somewhat unlikely, however, since NOD-SCID mice, in
addition to having virtually no B cells and T cells, also have
extremely low natural killer cell activity and almost no
complement activity, and myeloid lineage cells are defective
[34,35]. Clearly, though, further studies will be needed to more
precisely determine the role that CXCR5 and CXCL13 may be
playing in tumor growth.
Finally, the fact that high levels of murine CXCL13 were also
observed in NOD-SCID mice that developed tumors after
inoculation of either the R (AIDS-DLBCL) cell line or the
BCBL-1 (AIDS-PEL) cell line (Results, not shown) suggests
that the 2F7 cell line is not atypical of AIDS-lymphoma cell
lines, in terms of being able to promote murine CXCL13
overproduction in tumor-bearing NOD-SCID mice. It also
suggests that promotion of murine CXCL13 overproduction in
NOD-SCID mice is not restricted to AIDS-lymphoma cell lines
of the Burkitt subtype. The possibility also exists that
overexpression of murine CXCL13 may be a common
phenomenon in many NOD-SCID models of cancer, B cell-
related or not. Future studies are needed to examine this issue,
as it appears that no previous studies on murine CXCL13
expression in NOD-SCID models of cancer appear to have
been reported.
In summary, we have established a novel mouse/human
xenograft model of AIDS-BL lymphoma using the AIDS-BL cell
line, 2F7. In this model, greatly elevated levels of CXCR5 are
seen on the surface of tumor cells, and greatly elevated levels
of murine, but not human, CXCL13 are seen in the serum and
ascites of animals with tumors. These studies suggest that
non-tumor murine cells are responsible for the overproduction
of CXCL13 observed in this model, and raise the possibility that
immune cells and tumor cells may interact via the CXCR5/
CXCL13 axis in this model, and potentially, in human AIDS-
lymphoma as well. Further studies are needed to more
definitively define the role of the CXCR5/CXCL13 axis, both in
murine models, and in human AIDS-lymphoma.
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